We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+17.73%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$717M
AUM Growth
+$143M
Cap. Flow
+$179M
Cap. Flow %
24.96%
Top 10 Hldgs %
42.64%
Holding
176
New
63
Increased
14
Reduced
29
Closed
31

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$15.9M
2
RCUS icon
Arcus Biosciences
RCUS
+$9.44M
3
AVTX icon
Avalo Therapeutics
AVTX
+$9.44M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$9.12M
5
BPMC
Blueprint Medicines
BPMC
+$8.44M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$20.7M
2
SLNO
Soleno Therapeutics
SLNO
+$10.7M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$8.35M
4
NUVL
Nuvalent
NUVL
+$8.24M
5
AMGN icon
Amgen
AMGN
+$8.18M

Sector Composition

Rank Sector Weight
1 Healthcare 44.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
76
Nektar Therapeutics
NKTR
$2.39B
$1.71M 0.24%
87,494
– –
GLUE icon
77
Monte Rosa Therapeutics
GLUE
$1.4B
$1.65M 0.23%
+311,593
New +$1.57M
ONC
78
BeOne Medicines Ltd
ONC
$32.8B
$1.64M 0.23%
+88,167
New +$15.9M
SRRK icon
79
CALL
Scholar Rock
SRRK
$5.67B
$1.62M 0.23%
+202,100
New +$1.77M
SRRK icon
80
PUT
Scholar Rock
SRRK
$5.67B
$1.62M 0.23%
+202,100
New +$1.77M
FULC icon
81
CALL
Fulcrum Therapeutics
FULC
$273M
$1.51M 0.21%
+422,800
New +$3.14M
ACHL
82
DELISTED
Achilles Therapeutics
ACHL
$1.47M 0.21%
1,443,181
– –
SWTX
83
CALL
DELISTED
SpringWorks Therapeutics
SWTX
$1.4M 0.2%
+43,800
New +$1.64M
GALT icon
84
CALL
Galectin Therapeutics
GALT
$196M
$1.38M 0.19%
+500,000
New +$1.23M
GALT icon
85
PUT
Galectin Therapeutics
GALT
$196M
$1.38M 0.19%
+500,000
New +$1.23M
IBIO icon
86
iBio
IBIO
$69.5M
$1.33M 0.19%
600,000
– –
PYXS icon
87
CALL
Pyxis Oncology
PYXS
$168M
$1.32M 0.18%
358,600
+355,014
+9,900% +$1.24M
CMPS
88
Compass Pathways
CMPS
$1.53B
$1.28M 0.18%
202,908
-100,000
-33% -$706K
KOD icon
89
Kodiak Sciences
KOD
$2.6B
$1.24M 0.17%
476,586
– –
MRNS
90
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.24M 0.17%
706,154
– –
ROIV icon
91
Roivant Sciences
ROIV
$24.5B
$1.16M 0.16%
100,609
– –
CRVS icon
92
CALL
Corvus Pharmaceuticals
CRVS
$1.12B
$1.15M 0.16%
+218,300
New +$784K
OLMA icon
93
Olema Pharmaceuticals
OLMA
$1B
$1.1M 0.15%
+92,000
New +$1.18M
IFRX icon
94
InflaRx
IFRX
$250M
$1.08M 0.15%
704,987
– –
SGMT icon
95
Sagimet Biosciences
SGMT
$439M
$1.07M 0.15%
387,565
-25,000
-6% -$77.1K
JSPR icon
96
Jasper Therapeutics
JSPR
$21M
$1.04M 0.14%
55,175
-50,000
-48% -$996K
CATX icon
97
PUT
Perspective Therapeutics
CATX
$332M
$1.03M 0.14%
+77,100
New +$1.03M
PHGE icon
98
BiomX
PHGE
$1.99M
$911K 0.13%
+47,000
New +$1.7M
DCTH icon
99
Delcath Systems
DCTH
$422M
$906K 0.13%
100,370
– –
CLYM
100
Climb Bio
CLYM
$681M
$891K 0.12%
175,100
+75,100
+75% +$531K
2 3
4
5 6

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Ikarian Capital held 176 positions worth $717M, up 25% from $574M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Ikarian Capital deployed $179M of net new capital in Q3 2024, opening 63 new positions and adding to 14 existing holdings. Its largest new stake was BeOne Medicines Ltd: 88,167 shares worth $1.64M.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 56% a quarter earlier.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $20.7M trimmed.

  • Ikarian Capital's largest Q3 2024 buy was BeOne Medicines Ltd: 88,167 shares worth $1.64M.
  • Ikarian Capital added most to Arcus Biosciences in Q3 2024, an estimated $9.44M increase.
  • Ikarian Capital's biggest Q3 2024 reduction was Sarepta Therapeutics, cutting an estimated $20.7M.
  • Ikarian Capital fully exited Immunovant in Q3 2024, selling an estimated $8.17M.
  • Ikarian Capital's ten largest holdings make up 43% of its $717M portfolio in Q3 2024.
  • Ikarian Capital opened 63 new positions and closed 31 in Q3 2024.
  • Ikarian Capital's portfolio value rose 25% quarter-over-quarter to $717M.

Based on Ikarian Capital's 13F filing for Q3 2024, filed 14 Nov 2024.